IP Library Granted Patent US 9,079,927
Granted Patent B1
US 9,079,927 · App. 14/608,855 · Granted Jul 14, 2015

Substituted imidazolium compounds for treating disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,079,927
App. No.
14/608,855
Granted
Jul 14, 2015
Kind
B1
Abstract

The present disclosure relates to therapeutic compositions comprising substituted imidazoliums having multiple acidic groups. The compounds may be used to treat diseases or conditions such as those associated with bone, cancer, or pain. Compositions, dosage forms, methods of treating diseases or conditions, methods of preparation, and other related embodiments related to the substituted imidazoliums are also described herein.

Claims (17)

1. A compound represented by a formula:

wherein X − is F − , Br − , Cl − , I − , OH − , or acetate; and

M + is Na + , K + , or NH 4 + .

2. The compound of claim 1 , further represented by a formula,

3. The compound of claim 2 , wherein the compound is in a hydrate form.

4. A dosage form comprising the compound of claim 1 .

5. The dosage form of claim 4 , wherein the compound is no more than 0.1% (w/w) of the total amount of therapeutically active agent in the dosage form.

6. The dosage form of claim 4 , wherein the compound is at least 20% of the total amount of therapeutically active agent in the dosage form.

7. The dosage form of claim 4 , wherein the compound is at least 90% of the total amount of therapeutically active agent in the dosage form.

8. A compound represented by a formula:

wherein M + is Na + , K + , or NH 4 + .

9. The compound of claim 8 , wherein the compound is further represented by a formula,

10. The compound of claim 9 , wherein the compound is in a hydrate form.

11. A dosage form comprising the compound of claim 8 .

12. The dosage form of claim 8 , wherein the compound is no more than 0.1% (w/w) of the total amount of therapeutically active agent in the dosage form.

13. The dosage form of claim 8 , wherein the compound is at least 20% of the total amount of therapeutically active agent in the dosage form.

14. The dosage form of claim 8 , wherein the compound is at least 90% of the total amount of therapeutically active agent in the dosage form.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2015
From: TABUTEAU, HERRIOT
To: ANTECIP BIOVENTURES II LLC
Reel/Frame 034916/0336 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2015
From: DINKLA, ERIC K.H.
To: AXSOME THERAPEUTICS, INC.
Reel/Frame 034916/0404 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2015
From: AXSOME THERAPEUTICS, INC.
To: ANTECIP BIOVENTURES II LLC
Reel/Frame 034916/0572 →